Biosenta Inc (TSE:ZRO)
:ZRO
Want to see TSE:ZRO full AI Analyst Report?
Top Page
Biosenta Inc
(ZRO)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.05
▼(-40.00% Downside)
Action:Reiterated
Date:06/01/26
The score is primarily held down by weak financial performance: persistent large losses, negative free cash flow, and severely negative equity. Technicals add modest downside pressure due to a broader moving-average downtrend and negative MACD, while valuation remains challenged given the loss-making profile and no dividend support.
Positive Factors
Revenue Growth Momentum
Sharp TTM revenue growth demonstrates improving product adoption and market traction. A growing top line can provide the scale needed to absorb fixed costs, support investments in R&D and sales, and create a foundation for durable margin recovery if cost structure is managed.
Negative Factors
Deeply Negative Shareholders' Equity
Extremely negative shareholders' equity is a structural solvency concern that limits borrowing capacity and raises refinancing and dilution risk. This impaired capital base materially constrains financial flexibility and increases the likelihood of equity raises or restructuring over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Momentum
Sharp TTM revenue growth demonstrates improving product adoption and market traction. A growing top line can provide the scale needed to absorb fixed costs, support investments in R&D and sales, and create a foundation for durable margin recovery if cost structure is managed.
Read all positive factors
Biosenta Inc (ZRO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.74M
Dividend YieldN/A
Average Volume (3M)2.93K
Price to Earnings (P/E)―
Beta (1Y)2.28
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees5
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-0.07
Shares Outstanding34,768,887
10 Day Avg. Volume5,790
30 Day Avg. Volume2,930
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-0.40
Price to Sales (P/S)3296.23
P/FCF Ratio-8.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biosenta Inc Business Overview & Revenue Model
Company Description
Biosenta Inc., a Toronto-based Canadian firm established in 1986, specializes in the development, manufacturing, and sale of antimicrobial chemical compounds for both residential and commercial applications throughout the country. The company is a...
How the Company Makes Money
null...
Biosenta Inc Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.90K | 1.21K | 1.38K | 1.04K | 1.15K | 168.10K |
| Gross Profit | -2.21K | -1.78K | 835.00 | 427.00 | 728.00 | 99.11K |
| EBITDA | -1.40M | -1.39M | -1.09M | -6.24M | -1.24M | -2.03M |
| Net Income | -2.36M | -2.51M | -2.23M | -6.30M | -1.46M | -2.05M |
Balance Sheet | ||||||
| Total Assets | 92.24K | 110.33K | 113.54K | 107.59K | 256.08K | 263.66K |
| Cash, Cash Equivalents and Short-Term Investments | 10.38K | 26.49K | 8.53K | 5.88K | 27.26K | 111.88K |
| Total Debt | 973.87K | 694.59K | 5.55M | 5.62M | 94.77K | 152.43K |
| Total Liabilities | 11.16M | 10.17M | 7.99M | 7.96M | 3.18M | 2.86M |
| Stockholders Equity | -11.07M | -10.06M | -7.88M | -7.86M | -2.92M | -2.59M |
Cash Flow | ||||||
| Free Cash Flow | -428.46K | -481.24K | -779.35K | -566.35K | -504.43K | -672.29K |
| Operating Cash Flow | -426.81K | -455.38K | -779.35K | -550.79K | -504.43K | -672.29K |
| Investing Cash Flow | -1.65K | -25.86K | 0.00 | -15.56K | 0.00 | 0.00 |
| Financing Cash Flow | 434.62K | 499.20K | 781.99K | 544.97K | 419.81K | 739.86K |
Biosenta Inc Technical Analysis
Negative
0.08
Price Trends
0.06
Negative
0.07
Negative
0.09
Negative
Market Momentum
>-0.01
Negative
42.75
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ZRO, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.06, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.75 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ZRO.
Biosenta Inc Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
50 Neutral | C$2.20M | -1.22 | -129.49% | ― | -95.69% | 44.32% | |
45 Neutral | C$4.07M | -0.78 | -70.53% | ― | -2.34% | -19.25% | |
42 Neutral | C$1.74M | -0.71 | ― | ― | ― | ― | |
| ― | C$14.55M | -11.91 | -179.43% | ― | ― | -65.67% |
* Consumer Defensive Sector Average
TSE:ZRO
Biosenta Inc
0.05
-0.09
-64.29%
TSE:BGA
BioNeutra Global
0.03
0.00
0.00%
TSE:LFST
Lifeist Wellness
0.06
-0.03
-29.41%
TSE:PSYC
Psyched Wellness
0.02
-0.01
-40.00%
TSE:MOOO.X
Happy Supplements Inc.
0.35
-0.19
-35.19%
TSE:URAI
Pure to Pure Beauty Inc.
0.11
-0.05
-30.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.